Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FABP1 | P07148 | 1/20 | 0.40 |
| ▸ | FABP6 | P51161 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802479 | 0.90 | CTSS (0.43) | CTSSHPGDKCNA5KCNE1NPC1 | |
| SCHEMBL6808965 | 0.86 | TSHR (0.47) | CTSSSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6807801 | 0.81 | KCNA5 (0.39) | CTSSKCNA5KCNE1SMN1; SMN2 | |
| SCHEMBL10062683 | 0.79 | CTSS (0.48) | CTSSEPHX1HPGDSMN1; SMN2LMNA | |
| SCHEMBL6808220 | 0.79 | ROCK2 (0.42) | EPHX1HPGDSMN1; SMN2RAB9A | |
| SCHEMBL6808909 | 0.77 | SMN1; SMN2 (0.38) | KCNA5KCNE1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14873381 | 0.77 | KCNA5 (0.42) | KCNA5KCNE1SMN1; SMN2 | |
| SCHEMBL6798043 | 0.77 | OPRK1 (0.40) | EPHX1SMN1; SMN2LMNACNR2CNR1 | |
| SCHEMBL20217274 | 0.76 | KCNA5 (0.41) | KCNA5KCNE1SMN1; SMN2 | |
| SCHEMBL18886611 | 0.74 | EPHX1 (0.49) | CTSSEPHX1HPGDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | CTSS 1081/4885EPHX1 1603/4885HPGD 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.